Notice of AGM

About this update from Cambridge Cognition Holdings Plc

  04 June 2025   Cambridge Cognition Holdings plc ("Cambridge Cognition", the "Company" or the "Group") Posting of Annual Report & Notice of AGM   Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment , confirms that the Annual Report and Accounts for the year ended 31 December 2024 ("2024 Annual Report and Accounts") and the Notice of the Annual General Meeting ("AGM") have been published on the Company's website today. Hard copies have been posted to those shareholders who requested them.   The AGM is to be held at 9:00 am on 27 June 2025 at the registered office of the Company, Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU.   A copy of the 2024 Annual Report and Accounts and other documents are available on the Company's website: www.cambridgecognition.com   Enquiries:   Cambridge Cognition Holdings plc Rob Baker, Joint Managing Director and Chief Operating Officer   Tel: 012 2381 0700 [email protected] Panmure Liberum Limited (NOMAD and Joint Broker) Freddy Crossley / Will Goode / Mark Rogers Rupert Dearden   Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking) Dowgate Capital Limited (Joint Broker) David Poutney / Amber Philipps   Tel: 020 3903 7715 Hudson Sandler (Financial PR and IR) Dan de Belder / Hattie Dreyfus / Jackson Redley Tel: 020 7796 4133 [email protected]     Notes to Editors About Cambridge Cognition Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment. Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts.  The Company has identified four market sectors: ·      Clinical Studies for new pharmaceuticals; ·      Academic Research for scientists to understand CNS disorders; ·      Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and, ·      Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health. For further information, visit: www.cambridgecognition.com     END  

View stock analysis, news, and events for Cambridge Cognition Holdings Plc